218
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Epileptic seizures in anaplastic gangliogliomas

, , , , , , , , , , , , , , , , , & show all
Pages 227-233 | Received 04 Mar 2016, Accepted 26 Jul 2016, Published online: 23 Aug 2016
 

Abstract

Aim: Prevalence and predictors of epileptic seizures are unknown in the malignant variant of ganglioglioma.

Methods: In a retrospective exploratory dataset of 18 supratentorial anaplastic World Health Organization grade III gangliogliomas, we studied: (i) the prevalence and predictors of epileptic seizures at diagnosis; (ii) the evolution of seizures during tumor evolution; (iii) seizure control rates and predictors of epilepsy control after oncological treatments.

Results: Epileptic seizures prevalence progresses throughout the natural course of anaplastic gangliogliomas: 44% at imaging discovery, 67% at histopathological diagnosis, 69% following oncological treatment, 86% at tumor progression, and 100% at the end-of-life phase. The medical control of seizures and their refractory status worsened during the tumor’s natural course: 25% of uncontrolled seizures at histopathological diagnosis, 40% following oncological treatment, 45.5% at tumor progression, and 45.5% at the end-of-life phase. Predictors of seizures at diagnosis appeared related to the tumor location (i.e. temporal and/or cortical involvement). Prognostic parameters of seizure control after first-line oncological treatment were temporal tumor location, eosinophilic granular bodies, TP53 mutation, and extent of resection. Prognostic parameters of seizure control at tumor progression were a history of epileptic seizures at diagnosis, seizure control after first-line oncological treatment, eosinophilic granular bodies, and TP53 mutation.

Conclusion: Epileptic seizures are frequently observed in anaplastic gangliogliomas and both prevalence and medically refractory status worsen during the tumor’s natural course. Both oncological and antiepileptic treatments should be employed to improve the control of epileptic seizures and the quality of life of patients harboring an anaplastic ganglioglioma.

Acknowledgements

These physicians are greatly acknowledged (in alphabetical order): Georges Abi-Lahoud, Felipe Andreiuolo, Francine Chassoux, Frédéric Dhermain, Christelle Dufour, Myriam Edjlali-Goujon, Sylvie Godon-Hardy, Maria Koziak, Ludovic Lacroix, Elisabeth Landré, Emmanuelle Lechapt-Zalcman, Laurence Legrand, Michael Mann, Jean-Louis Mas, Eric Méary, Charles Mellerio, Olivier Naggara, François Nataf, Catherine Oppenheim, Christophe Pellegrino, Denis Trystram, Baris Turak.

Disclosure statement

The authors report no declaration of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.